Feature Channels:

Pharmaceuticals

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Drug Trial for Solid Cancer Tumors, Lynch Syndrome Awareness, Side Effects for Prostate Cancer Treatments, and More in the Cancer News Source

Click here to go directly to the Cancer News Source

Medicine

Channels:

Midazolam, Seizures, Status Epilepticus, ambulance services, Benzodiazepines

After a Clinical Trial on Midazolam for Seizures, Emergency Use of the Drug Rises

meurer.jpg

A new study investigated if previous research on midazolam’s efficacy as a seizure treatment affected whether ambulances nationwide were choosing the drug over other benzodiazepines for seizure patients.

Medicine

Channels:

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 24-Mar-2017 4:00 PM EDT

Medicine

Channels:

Exercise, Diabetes, Obesity, Muscular Dystrophy

SLU Scientists Take Aim at Diabetes and Obesity with Exercise in a Pill

BurrisandWalker-min.jpg

With a series of new grants, Saint Louis University researchers will develop the potential of two nuclear receptors that control muscle metabolism.

Medicine

Channels:

small molecule drugs, ONC201, Prostate Cancer, Endometrial Cancer, Phase II clinical trials, New Jersey, Rutgers University

‘First in Human’ Trial Defines Safe Dosage for Small Molecule Drug ONC201 for Solid Cancer Tumors

RutgersCancer351.JPG

A ‘first in human’ clinical trial examining the small molecule drug ONC201 in cancer patients with advanced solid tumors shows that this investigational drug is well tolerated at the recommended phase II dose. That’s according to Rutgers Cancer Institute of New Jersey investigators whose research also showed early signs of clinical benefit in patients with advanced prostate and endometrial cancers.

Medicine

Channels:

Caution Needed for Drugs in Development for Most Common Malignant Pediatric Brain Tumor

00191504-003_wm.jpg

Inhibiting the Ezh2 enzyme may be counterproductive for treatment of certain cancers, including the aggressive brain tumor Group 3 medulloblastoma

Medicine

Channels:

New Drug Test Aids Clinicians with Prescription Drug Monitoring in Patients on Chronic Opioids

Drug diversion is a significant contributing factor in prescription pain medication misuse and deadly overdoses. A new oral fluid monitoring test, announced today by Cordant Health Solutions, www.cordantsolutions.com, reports more detailed and actionable information to clinicians than urine drug tests, which can potentially improve therapy adherence, patient safety, and help to identify drug diversion.

Medicine

Channels:

Genetics, Psychiatry, Molecular Biology, Neurobiology, Depression, Mental Health, Pharmaceutical Chemistry, Neuroscience

Mouse Study Identifies New Method for Treating Depression

depression_pixabay.jpg

Standard antidepressant medications don’t work for everyone, and even when they do they are slow to kick in. In an effort to find better depression treatments, researchers at University of California San Diego School of Medicine discovered that inhibiting an enzyme called Glyoxalase 1 (GLO1) relieves signs of depression in mice. Moreover, inhibiting GLO1 worked much faster than the conventional antidepressant Prozac.

Medicine

Channels:

Bioinformatics, Genetics, Cancer, Pharmaceutical Science, Precision Medicine, CRISPR/Cas9

Gene Editing Technique Helps Find Cancer’s Weak Spots

synthetic_lethal_interactions_network_ideker.jpg

Genetic mutations that cause cancer also weaken cancer cells, allowing researchers to develop drugs that will selectively kill them. This is called “synthetic lethality” because the drug is only lethal to mutated (synthetic) cells. Researchers at UC San Diego School of Medicine and Jacobs School of Engineering developed a method to search for synthetic-lethal gene combinations. The technique, published March 20 in Nature Methods, uncovered 120 new opportunities for cancer drug development.

Medicine

Channels:

Researchers Discover Key to Drug Resistance in Common Breast Cancer Treatment

nettles_kendall.jpg

Scientists from the Florida campus of The Scripps Research Institute (TSRI), the University of California (UC), San Diego and the University of Illinois have found that two immune system molecules may be key to the development of drug resistance in estrogen-driven breast cancers.







Chat now!